Epithelial Ovarian Cancer

P2/3, N=46, Not yet recruiting, AstraZeneca AB

Due to the low mutation frequency of commonly studied genes, cumulative mutational burden may better explain the progression and pathogenesis of endometriosis-associated epithelial ovarian carcinoma than any single mutation. CTNNB1 may be associated with the development of endometrioid ovarian carcinoma. Future studies may consider the use of polygenic scores for risk assessment of endometriosis-associated ovarian cancer.

Accordingly, the combination of ganetespib (an HSP90 inhibitor) and temsirolimus (a FDA approved-mTOR inhibitor) with cisplatin synergistically reduced colony formation and microtissues cell growth in vitro by increasing DNA-damage and apoptosis and in vivo enhancing mouse survival. Notably, all these data were confirmed also in Pt-resistant Non Small Cell Lung Cancer models. Collectively, our findings identify a promising new antitumor strategy for the treatment of Pt-resistance in cancer patients.

P=N/A, N=98, Recruiting, The First Hospital of Jilin University

Given its rarity, chemoresistance, and underrepresentation in large trials, OCCC requires histology-specific therapeutic strategies informed by molecular profiling. Ongoing research into biomarker-driven therapies and combination regimens holds the potential to transform outcomes for this challenging ovarian cancer subtype.

P3, N=132, Recruiting, Ente Ospedaliero Ospedali Galliera | Not yet recruiting --> Recruiting

Notably, arginine restriction or pharmacological inhibition of DDX3X did effectively suppress both primary tumor growth and omental metastasis in mouse models. Collectively, our findings reveal that arginine is a metabolic vulnerability in omental metastasis of EOC, indicating that arginine restriction and DDX3X inhibition represent promising therapeutic strategies.

This study confirms the importance of limiting HBOC genetic testing to clinically actionable genes in routine clinical practice. The re-evaluation and the prioritization of VUS are also essential, since they allow clinical laboratories to manage their resources more efficiently.

These findings highlight FBXW7 as a potential tumor suppressor in endometriosis-associated ovarian carcinoma, with effect on cell proliferation, migration, and EMT regulation. The FBXW7-vimentin association may represent previously unrecognized pathway with therapeutic relevance in ovarian carcinoma.

P1/2, N=22, Recruiting, Case Comprehensive Cancer Center | Trial completion date: Mar 2026 --> Sep 2026 | Trial primary completion date: Mar 2026 --> Sep 2026

P1/2, N=36, Recruiting, Beijing Biotech

The study highlights elevated CA-125 and symptoms as primary recurrence indicators, questioning physical exam efficacy, and stresses the financial and emotional burden of frequent hospital visits.